Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFRT Combined With Immunochemotherapy for GEJA
NCT07072351Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2025
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety and tolerability at 3 months and Objective Response Rate. Started Sep 2025; status: recruiting.
Beyond the preview
Go deeper on NCT07072351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072351.